Macitentan |
N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide |
(CAS 441798-33-0) |
|
Description: |
Macitentan (trade name Opsumit) is an endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).[1] The other two ERAs marketed as of 2014 are bosentan and ambrisentan.[1] Macitentan is a dual ERA, meaning that it acts as an antagonist of two endothelin (ET) receptor subtypes, ETA and ETB.[1] However, macitentan has a 50-fold increased selectivity for the ETA subtype compared to the ETB subtype.[2] The drug received approval from the U.S. Food and Drug Administration (FDA) on October 13, 2013.[3] |
Product No. |
KT00036 |
Product Name |
Macitentan |
Synonyms |
|
Formal Name |
N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide |
CAS Number |
441798-33-0 |
Molecular Formula |
C19H20Br2N6O4S |
Formula Weight |
588.27 |
Formulation |
A crystalline solid |
Purity |
98%min |
Stability |
1 year |
Storage |
-20°C |
Shipping |
USD45 for Europe and USA. No shipping charge once amount reach USD500. |
Quality Control |
HNMR,CNMR,LCMS,HPLC,IR,etc. |
Price & Availability |
In Stock. Price Negotiated. |
|
Related Products: |
Fingolimod (FTY720) HCl
Cyclopamine
Vismodegib (GDC-0449)
Bosentan
Bosentan Hydrate
Sitaxentan sodium |
|